ProShare Advisors LLC Has $178.63 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTX

ProShare Advisors LLC raised its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 401,244 shares of the pharmaceutical company’s stock after acquiring an additional 18,214 shares during the period. ProShare Advisors LLC owned about 0.16% of Vertex Pharmaceuticals worth $178,634,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in VRTX. Price T Rowe Associates Inc. MD boosted its position in Vertex Pharmaceuticals by 72.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,917,227 shares of the pharmaceutical company’s stock valued at $1,414,331,000 after buying an additional 1,226,527 shares in the last quarter. Jennison Associates LLC increased its holdings in shares of Vertex Pharmaceuticals by 21.5% during the second quarter. Jennison Associates LLC now owns 6,151,505 shares of the pharmaceutical company’s stock worth $2,738,650,000 after buying an additional 1,089,063 shares in the last quarter. Nuveen LLC bought a new position in shares of Vertex Pharmaceuticals in the 1st quarter valued at $484,053,000. Goldman Sachs Group Inc. boosted its holdings in shares of Vertex Pharmaceuticals by 28.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,775,194 shares of the pharmaceutical company’s stock valued at $860,650,000 after acquiring an additional 398,460 shares in the last quarter. Finally, Alyeska Investment Group L.P. boosted its holdings in shares of Vertex Pharmaceuticals by 456.9% during the 1st quarter. Alyeska Investment Group L.P. now owns 431,804 shares of the pharmaceutical company’s stock valued at $209,347,000 after acquiring an additional 354,269 shares in the last quarter. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Down 1.6%

Shares of Vertex Pharmaceuticals stock opened at $409.47 on Monday. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.88. The company has a market cap of $103.89 billion, a P/E ratio of 29.27 and a beta of 0.36. The business has a 50-day moving average price of $404.55 and a two-hundred day moving average price of $429.12.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.58 by $0.22. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The company had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. During the same quarter in the previous year, the firm earned $4.38 earnings per share. Vertex Pharmaceuticals’s quarterly revenue was up 11.0% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on VRTX shares. Royal Bank Of Canada cut their price target on Vertex Pharmaceuticals from $423.00 to $415.00 and set a “sector perform” rating on the stock in a research note on Tuesday, November 4th. Evercore ISI cut their target price on shares of Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating on the stock in a research report on Thursday, September 11th. Canaccord Genuity Group decreased their price target on shares of Vertex Pharmaceuticals from $424.00 to $411.00 and set a “hold” rating for the company in a research report on Wednesday, August 6th. Stifel Nicolaus dropped their price target on shares of Vertex Pharmaceuticals from $455.00 to $445.00 and set a “hold” rating for the company in a research note on Tuesday, November 4th. Finally, Barclays lifted their price target on shares of Vertex Pharmaceuticals from $408.00 to $414.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $489.10.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.